{"preliminary_commentary":{"by_channel":{"youtube":125,"podcast":88,"x_thread":32,"x_video":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03336333\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["zanubrutinib"],["zanubrutinib","venetoclax"]],"indication":"previously untreated CLL/SLL","name":"SEQUOIA","nct_id":"NCT03336333","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sequoia-nct03336333. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SEQUOIA","arms":[{"description":"Participants will receive bendamustine plus rituximab for up to six 28-day cycles (Arm B)","label":"Cohort 1: Bendamustine + Rituximab","type":"EXPERIMENTAL"},{"description":"Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm A)","label":"Cohort 1: Zanubrutinib","type":"EXPERIMENTAL"},{"description":"Participants will receive bendamustine plus rituximab for up to six 28-day cycles (Arm B, China only)","label":"Cohort 1a (China only): Bendamustine + Rituximab","type":"EXPERIMENTAL"},{"description":"Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm A, China only)","label":"Cohort 1a (China only): Zanubrutinib","type":"EXPERIMENTAL"},{"description":"Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm C)","label":"Cohort 2: Zanubrutinib","type":"EXPERIMENTAL"},{"description":"Approximately 110 participants, 50 without del17p and 60 with del\\[17p\\] or TP53 mutation will receive zanubrutinib plus venetoclax; Participants will also receive zanubrutinib starting on Cycle 1 Day 1 then daily for a minimum of 27 cycles, or until unacceptable toxicity or disease progression, whichever occurs first. Participants will receive venetoclax starting Cycle 4 Day 1 according to a 5-week dose-up schedule then daily until unacceptable toxicity, disease progression, or for a maximum of 24 cycles. Each cycle is 28 days. (Arm D)","label":"Cohort 3: Venetoclax + Zanubrutinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-10-31","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":{"count":590,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Zanubrutinib","otherNames":["BGB-3111","BRUKINSA"],"type":"DRUG"},{"name":"Bendamustine","otherNames":["Treanda, Ribomustin, and Levact"],"type":"DRUG"},{"name":"Rituximab","otherNames":["Rituxan, MabThera"],"type":"DRUG"},{"name":"Venetoclax","otherNames":["Venclexta, Venclyxto"],"type":"DRUG"}],"last_update":"2026-03-09","lead_sponsor":"BeiGene","official_title":"An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2021-05-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)","timeFrame":"Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021)"}],"references":[{"citation":"Mu S, Tang Z, Novotny W, Tawashi M, Li TK, Ou Y, Sahasranaman S. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer Chemother Pharmacol. 2020 Feb;85(2):391-399. doi: 10.1007/s00280-019-04015-w. Epub 2019 Dec 26.","pmid":"31875923","type":"RESULT"},{"citation":"Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, Simpson D, Shadman M, Ganly PS, Laurenti L, Opat S, Tani M, Ciepluch H, Verner E, Simkovic M, Osterborg A, Trneny M, Tedeschi A, Paik JC, Kuwahara SB, Feng S, Ramakrishnan V, Cohen A, Huang J, Hillmen P, Brown JR. Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion. Haematologica. 2021 Sep 1;106(9):2354-2363. doi: 10.3324/haematol.2020.259432.","pmid":"33054121","type":"RESULT"},{"citation":"Munir T, Martinez-Calle N, Xu S, Yang K, Ge X, Ali AK, Mohseninejad L, Dobi B, Rakonczai P, Ma H, Williams R, Aldairy W, Lamanna N. Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Oncol Ther. 2025 Dec;13(4):1055-1070. doi: 10.1007/s40487-025-00380-0. Epub 2025 Sep 13.","pmid":"40944848","type":"DERIVED"},{"citation":"Shadman M, Munir T, Ma S, Lasica M, Tani M, Robak T, Flinn IW, Brown JR, Ghia P, Ferrant E, Tam CS, Janowski W, Jurczak W, Xu L, Tian T, Lefebure M, Agresti S, Hirata J, Tedeschi A. Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. J Clin Oncol. 2025 Jul 20;43(21):2409-2417. doi: 10.1200/JCO-25-00758. Epub 2025 May 31.","pmid":"40448577","type":"DERIVED"},{"citation":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Simkovic M, Osterborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trneny M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, Garcia-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W. Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. J Clin Oncol. 2025 Mar;43(7):780-787. doi: 10.1200/JCO-24-02265. Epub 2024 Dec 8.","pmid":"39647999","type":"DERIVED"},{"citation":"Kittai AS, Allan JN, James D, Bridge H, Miranda M, Yong ASM, Fam F, Roos J, Shetty V, Skarbnik A, Davids MS. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024 Jun 11;8(11):2861-2869. doi: 10.1182/bloodadvances.2023012142.","pmid":"38598745","type":"DERIVED"},{"citation":"Moslehi JJ, Furman RR, Tam CS, Salem JE, Flowers CR, Cohen A, Zhang M, Zhang J, Chen L, Ma H, Brown JR. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. Blood Adv. 2024 May 28;8(10):2478-2490. doi: 10.1182/bloodadvances.2023011641.","pmid":"38502198","type":"DERIVED"},{"citation":"Ghia P, Barnes G, Yang K, Tam CS, Robak T, Brown JR, Kahl BS, Tian T, Szeto A, Paik JC, Shadman M. Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab. Curr Med Res Opin. 2023 Nov;39(11):1505-1511. doi: 10.1080/03007995.2023.2262381. Epub 2023 Oct 12.","pmid":"37752878","type":"DERIVED"},{"citation":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Simkovic M, Shadman M, Osterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trneny M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5. Epub 2022 Jul 7.","pmid":"35810754","type":"DERIVED"}],"start_date":{"date":"2017-10-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","url":"https://clinicaltrials.gov/study/NCT03336333"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sequoia-nct03336333"}